Stockreport

Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease

Wave Life Sciences Ltd. - Ordinary Shares  (WVE) 
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am Check Earnings Report
PDF WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo No difference in total HTT protein or neurofila [Read more]